Precision oncology increasingly relies on companion diagnostics to identify patients eligible for targeted cancer therapies. The Food and Drug Administration (FDA) frequently treats these tests as essential to the safe and effective use of corresponding drugs, embedding them in clinical trial design, regulatory approval, and product labeling. At the same time, the Supreme Court’s decisions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and its progeny have significantly narrowed the scope of patent protection for diagnostic methods, particularly those based on correlations between biomarkers and therapeutic outcomes. This Article argues that, despite the erosion of patent eligibility, competition in the companion diagnostics market has not meaningfully expanded. Instead, regulatory design has emerged as a functional substitute for patent protection. The integration of diagnostics into drug development, the product-specific nature of FDA approval and labeling, and the evidentiary burdens imposed by the premarket approval pathway collectively create substantial barriers to entry for follow-on diagnostics. These features operate as a form of de facto exclusivity, enabling sponsors to maintain control over diagnostic markets even in the absence of enforceable patent rights. These dynamics are further reinforced by clinical and reimbursement practices. While off-label prescribing and insurance coverage policies often expand access to oncology therapies beyond their FDA-approved indications, those practices do not similarly reduce barriers to entry for competing companion diagnostics. Physicians may prescribe therapies more flexibly than labeling contemplates, but alternative diagnostics still face substantial regulatory and evidentiary hurdles before they can be marketed or broadly adopted for use with those therapies. By situating companion diagnostics at the intersection of FDA regulation, post-Mayo patent doctrine, and oncology reimbursement practices, this Article challenges the assumption that limiting patent protection alone is sufficient to promote competition and access in companion diagnostic markets. It concludes that meaningful reform must address the structure of regulatory approval itself, including pathways for biomarker-based approval, mechanisms for demonstrating diagnostic comparability, and more flexible evidentiary standards for follow-on tests.